EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world effectiveness and safety of osilodrostat in Cushing's syndrome: a retrospective phase IV study

Rosario Pivonello iD, Chiara Simeoli, Nicola Di Paola, Ilaria Bonaventura iD, Davide Ferrari iD, Giacomo Voltan, Roberta Giordano iD, Maria Elena Aloini, Ylenia Alessi, Marianna Martino, Emanuele Ferrante iD, Federico Gatto und 12 weitere

The Journal of Clinical Endocrinology & Metabolism · 28.07.2026

DOI: 10.1210/clinem/dgag297 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 28.07.2026. Verfasst von Rosario Pivonello und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery, Section of Endocrinology, Diabetology, Andrology and Nutrition, University of Naples Federico II, Naples…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Recordati Rare Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Osilodrostat has demonstrated efficacy in clinical trials for Cushing's syndrome (CS). Real-world data remain limited.

Objective

To assess the real-world effectiveness and safety of osilodrostat in a large cohort of CS patients. Design and setting Multicenter, retrospective, phase IV study across 11 Italian endocrine referral centers. Patients One hundred CS patients (74% pituitary, 16% adrenal, 10% ectopic). Main outcome measures Primary endpoint was the percentage of patients with urinary free cortisol (UFC) ≤ upper limit of normal (ULN) at their last observation. Secondary endpoints included biochemical and hormonal control, clinical outcomes, quality of life (QoL), and adverse events (AEs).

Results

Eighty-one percent of patients had normal UFC levels at last observation, 92% at least once within the study period. Excluding 12 patients with normal baseline UFC levels, 78.4% of patients had normal UFC levels at their last observation, whereas 90.9% at least once within the study period. The mean ± SD (median, range) time to the first normalization of UFC levels, in the 80 patients who achieved normalization, was 92.1 ± 86.3 (67.5, 8-455) days, at a mean ± SD (median, range) osilodrostat dose of 7.2 ± 6.8 (5, 1-40) mg/day. Significant reductions in late-night salivary cortisol and morning serum cortisol levels were observed. Improvements were noted in anthropometric parameters, blood pressure, glucose metabolism, clinical signs, and QoL. AEs occurred in 29% of patients, mostly mild-to-moderate; adrenal insufficiency was the most common AE reported in 20% of patients. Hormonal control and safety profiles were consistent across CS etiologies.

Conclusion

Osilodrostat is effective, generally well tolerated in routine clinical practice, representing a valuable therapy for CS management, able to achieve rapid and sustained hormonal control, significant metabolic, cardiovascular, clinical, and QoL improvements with a well-tolerated safety profile.

Schlagwörter

Stichwörter der Autor:innen

Cushing's diseaseCushing's syndromeOsilodrostatendogenous hypercortisolismreal-world evidencesteroidogenesis inhibitor

Autor:innen und Institutionen

  • Department of Clinical Medicine and Surgery, Section of Endocrinology, Diabetology, Andrology and Nutrition, University of Naples Federico II, Naples, Italy.
  • UNESCO Chair for Health Education and Sustainable Development, University of Naples Federico II, Naples, Italy.
  • Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
  • Endocrinology Unit, University of Padua, Padua, Italy.
  • Department of Medicine (DIMED), University of Padua; Endocrinology Unit, University Hospital of Padua, Padua, Italy.
  • Department of Biological and Clinical Sciences, University of Turin, Turin, Italy.

ORCID-Profile: Rosario Pivonello, Ilaria Bonaventura, Davide Ferrari, Roberta Giordano, Emanuele Ferrante, Soraya Puglisi, Giovanna Mantovani, Giorgio Arnaldi, Antonio Stigliano, Emanuela Arvat, Mattia Barbot, Carla Scaroni, Annamaria Colao

Förderung

  • Recordati Rare Diseases

Zitieren

APA

Pivonello, R., Simeoli, C., Di Paola, N., Bonaventura, I., Ferrari, D., Voltan, G., Giordano, R., Aloini, M. E., Alessi, Y., Martino, M., Ferrante, E., Gatto, F., Puglisi, S., Rochira, V., Ferone, D., Mantovani, G., Arnaldi, G., Ferraù, F., Stigliano, A., …, & Colao, A. (2026). Real-world effectiveness and safety of osilodrostat in Cushing's syndrome: a retrospective phase IV study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag297

Vancouver

Pivonello R, Simeoli C, Di Paola N, Bonaventura I, Ferrari D, Voltan G, et al. Real-world effectiveness and safety of osilodrostat in Cushing's syndrome: a retrospective phase IV study. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag297

BibTeX
@article{Pivonello2026,
  author = {Pivonello, Rosario and Simeoli, Chiara and Di Paola, Nicola and Bonaventura, Ilaria and Ferrari, Davide and Voltan, Giacomo and Giordano, Roberta and Aloini, Maria Elena and Alessi, Ylenia and Martino, Marianna and Ferrante, Emanuele and Gatto, Federico and Puglisi, Soraya and Rochira, Vincenzo and Ferone, Diego and Mantovani, Giovanna and Arnaldi, Giorgio and Ferraù, Francesco and Stigliano, Antonio and Arvat, Emanuela and Barbot, Mattia and Scaroni, Carla and Isidori, Andrea M and Colao, Annamaria},
  title = {Real-world effectiveness and safety of osilodrostat in Cushing's syndrome: a retrospective phase IV study},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag297}
}
Kostenlos starten →